ATE335515T1 - Morpholinobildgebung und therapie - Google Patents

Morpholinobildgebung und therapie

Info

Publication number
ATE335515T1
ATE335515T1 AT02731189T AT02731189T ATE335515T1 AT E335515 T1 ATE335515 T1 AT E335515T1 AT 02731189 T AT02731189 T AT 02731189T AT 02731189 T AT02731189 T AT 02731189T AT E335515 T1 ATE335515 T1 AT E335515T1
Authority
AT
Austria
Prior art keywords
target site
morpholino
agent
conjugate
mammal
Prior art date
Application number
AT02731189T
Other languages
English (en)
Inventor
Donald J Hnatowich
Mary Rusckowski
Guozheng Liu
Original Assignee
Univ Massachusetts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Massachusetts filed Critical Univ Massachusetts
Application granted granted Critical
Publication of ATE335515T1 publication Critical patent/ATE335515T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0495—Pretargeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Medicinal Preparation (AREA)
AT02731189T 2001-03-30 2002-04-01 Morpholinobildgebung und therapie ATE335515T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27980901P 2001-03-30 2001-03-30
US34179401P 2001-12-21 2001-12-21

Publications (1)

Publication Number Publication Date
ATE335515T1 true ATE335515T1 (de) 2006-09-15

Family

ID=26959899

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02731189T ATE335515T1 (de) 2001-03-30 2002-04-01 Morpholinobildgebung und therapie

Country Status (6)

Country Link
US (1) US6899864B2 (de)
EP (1) EP1372741B1 (de)
AT (1) ATE335515T1 (de)
AU (1) AU2002303181A1 (de)
DE (1) DE60213771T2 (de)
WO (1) WO2002078638A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
EP1615995A4 (de) * 2003-04-15 2007-12-19 Immunomedics Inc Morpholino-darstellung und therapie durch amplifikations-targeting
US20050260131A1 (en) * 2004-05-20 2005-11-24 General Electric Company Pharmaceuticals for enhanced delivery to disease targets
US20060057062A1 (en) * 2004-09-10 2006-03-16 Trotter Dinko G Compositions and methods useful in pretargeted imaging
US7524829B2 (en) * 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
US20070009435A1 (en) * 2005-07-06 2007-01-11 Syud Faisal A Compositions and methods for enhanced delivery to target sites
WO2008088865A2 (en) * 2007-01-19 2008-07-24 University Of Massachusetts Antisense and pretargeting optical imaging
ES2738700T3 (es) 2009-02-13 2020-01-24 Immunomedics Inc Inmunoconjugados con un enlace escindible intracelularmente
KR100991716B1 (ko) * 2009-10-22 2010-11-04 경북대학교 산학협력단 광학영상 조영제, 그 용도 및 장치
CA2782194C (en) 2009-12-02 2018-01-16 Immunomedics, Inc. Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
US8198429B2 (en) 2010-08-09 2012-06-12 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
CN103501825B (zh) 2011-05-02 2017-03-15 免疫医疗公司 用于小体积施用的同种异型选择的抗体的超滤浓缩
EP2885002A4 (de) 2012-08-14 2016-04-20 Ibc Pharmaceuticals Inc Umleitung t-zell-bispezifischer antikörper zur behandlung von krankheiten
AU2013360335B2 (en) 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
KR102384693B1 (ko) * 2013-03-12 2022-04-07 유니버시티 오브 유타 리서치 파운데이션 세포사멸 유도용 조성물 및 방법
US20140308205A1 (en) * 2013-04-12 2014-10-16 University Of Massachusetts Medical School Trifunctional and completely clearable specific targeting agents and methods thereof
EP3107577B1 (de) 2014-02-21 2024-03-20 IBC Pharmaceuticals, Inc. Krankheitstherapie durch induktion einer immunantwort gegen trop-2-exprimierende zellen
CN106029098A (zh) 2014-02-25 2016-10-12 免疫医疗公司 人源化rfb4抗cd22抗体
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
CA2961774C (en) 2014-10-07 2023-05-23 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
US9797907B2 (en) 2015-04-22 2017-10-24 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
JP6980980B2 (ja) 2015-06-25 2021-12-15 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
EP3316885B1 (de) 2015-07-01 2021-06-23 Immunomedics, Inc. Antikörper-sn-38-immunkonjugate mit einem cl2a-linker
JP7048617B2 (ja) * 2016-12-19 2022-04-05 ヴェンタナ メディカル システムズ， インク． ペプチド核酸コンジュゲート
EP4178624A2 (de) 2020-07-07 2023-05-17 Bionecure Therapeutics, Inc. Maytansinoide als adc-nutzlasten und deren verwendung zur behandlung von krebs
JP2024515104A (ja) 2021-04-20 2024-04-04 テラパワー， エルエルシー Ａｃ－２２５生成のためのチタニアに基づくジェネレータ
JPWO2022239720A1 (de) 2021-05-10 2022-11-17

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927193A (en) * 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies
US4361544A (en) * 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4444744A (en) * 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4460561A (en) * 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4468457A (en) * 1981-06-01 1984-08-28 David M. Goldenberg Method for producing a CSAp tryptic peptide and anti-CSAp antibodies
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4479895A (en) * 1982-05-05 1984-10-30 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US4818709A (en) * 1983-01-21 1989-04-04 Primus Frederick J CEA-family antigens, Anti-CEA antibodies and CEA immunoassay
US4460459A (en) * 1983-02-16 1984-07-17 Anschutz Mining Corporation Sequential flotation of sulfide ores
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
US4782840A (en) * 1984-03-02 1988-11-08 Neoprobe Corporation Method for locating, differentiating, and removing neoplasms
US5185444A (en) * 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
AU5661386A (en) * 1985-03-15 1986-10-13 Stirchak, E. Stereoregular polynucleotide-binding polymers
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4932412A (en) * 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
AU3222793A (en) 1991-11-26 1993-06-28 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
JPH08500335A (ja) * 1992-05-06 1996-01-16 イムノメディクス，インコーポレイテッド 手術，血管内手技または内視鏡手技における腫瘍および病変の検出と治療
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
EP0837696B1 (de) * 1995-06-07 2010-02-24 Immunomedics, Inc. Verbesserte abgabe von diagnostischen und therapeutischen stoffen an einem zielort

Also Published As

Publication number Publication date
EP1372741A4 (de) 2004-06-16
WO2002078638A3 (en) 2003-02-13
AU2002303181A1 (en) 2002-10-15
DE60213771T2 (de) 2007-08-16
EP1372741A2 (de) 2004-01-02
WO2002078638A2 (en) 2002-10-10
DE60213771D1 (en) 2006-09-21
US20030003102A1 (en) 2003-01-02
US6899864B2 (en) 2005-05-31
EP1372741B1 (de) 2006-08-09

Similar Documents

Publication Publication Date Title
ATE335515T1 (de) Morpholinobildgebung und therapie
ATE365562T1 (de) Zielgerichtete kombinations-immuntherapie für krebs
DK0841949T3 (da) Anvendelse af saccharid-konjugater
CY1109786T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματικων ασθενειων με την χρησιμοποιηση ενος διαλυτου μοριου ctla4
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
PT907379E (pt) Agentes de contraste bioactivados para imagiologia de diagnostico
EP0837696A4 (de) Verbesserte abgabe von diagnostischen und therapeutischen stoffen an einem zielort
WO2001082975A3 (en) Membrane-permeant peptide complexes for medical imaging
DK0627940T3 (da) Anvendelse af immunokonjugater til diagnose og/eller terapi af vaskulariserede tumorer
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
WO1999067284A3 (en) Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
AU2002326610A1 (en) Multicomponent assemblies having enhanced binding properties for diagnosis and therapy
ATE349446T1 (de) Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
WO2001075454A3 (en) Diagnosis and treatment of alzheimer's disease
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
DK1594542T3 (da) Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer
WO2004074434A3 (en) Methods and compositions for administering therapeutic and diagnostic agents
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
WO2001098294A3 (en) Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
DK1237584T3 (da) Receptorbindende konjugater
DE60320398D1 (de) Methoden und medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs
DE60027905D1 (de) Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
DE69921486D1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
WO2001097848A3 (en) Vitronectin receptor antagonist pharmaceuticals

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties